Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Artisan Mid Cap Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Artisan Mid Cap Fund delivered solid Q4 returns despite underperforming its growth benchmark due to healthcare and semiconductor headwinds. Biotech setbacks at Argenx and Ascendis overshadowed strong consumer and software performance."
Artisan Mid Cap Fund generated positive absolute returns in Q4 2023 but underperformed the Russell Midcap Growth Index, primarily due to security selection within healthcare and information technology. Healthcare was the weakest performer for the year, driven by biotech holdings including Argenx and Ascendis, which faced R&D setbacks despite solid commercial progress. Semiconductor holdings experienced cyclical pressures, though the manager expects these downturns to be short-lived. The portfolio benefited from strong performance in consumer discretionary and communication services, with notable contributors including Chipotle, DexCom, and Shopify. For the full year, the portfolio generated strong absolute returns that meaningfully outperformed the broad Russell Midcap Index. The manager initiated new positions in Equifax, Celsius, and Xylem while ending campaigns in Agilon and BioNTech. Looking ahead, the team believes they enter 2024 with attractive opportunities across sectors, focusing on high-quality franchises with positive profit cycle outlooks and secular growth drivers.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The manager demonstrates high conviction through concentrated positions in named holdings with detailed thesis explanations. Specific position sizing language like 'largest position' and 'full weight' indicates strong conviction. The Garden/Crop/Harvest framework shows deliberate capital allocation based on conviction levels. Multiple holdings are discussed with multi-year investment horizons and specific catalysts.
Growth Outlook
The manager acknowledges continued macro-driven volatility and uncertainty about the economy's direction, particularly around the soft versus hard landing debate and interest rate cycle. However, they note resilient economic data and better-than-expected corporate earnings, suggesting a cautiously optimistic but measured outlook on markets.
Risk Appetite
The portfolio maintains selective exposure with new Garden positions initiated and some positions trimmed due to valuation discipline. The manager is actively deploying capital in specific opportunities while maintaining a measured approach to risk, neither aggressively risk-on nor defensive.
Capital Deployment
The manager initiated three new Garden positions (Equifax, Celsius, Xylem) and made notable adds to existing positions like DexCom and Quanta Services. However, they also trimmed several positions and ended two investment campaigns. The activity suggests selective deployment rather than aggressive capital deployment, with no specific cash level changes mentioned.
Forward Guidance
The manager expresses confidence in their process and believes they enter 2024 with attractive opportunities across sectors. However, they acknowledge much uncertainty about economic direction and emphasize patience and selectivity rather than aggressive deployment.
Language Signal
Language is balanced between opportunity recognition and risk acknowledgment. Terms like 'attractive opportunities,' 'compelling profit cycles,' and 'secular growth drivers' are offset by discussions of 'uncertainty,' 'cyclical pressures,' and 'setbacks.' Overall tone is measured and professional.
Perceived Risk
The manager acknowledges multiple risk factors including cyclical semiconductor pressures, biotechnology funding concerns in higher rate environments, macroeconomic uncertainty affecting customer spending, and potential extended downturns. However, these risks are discussed as manageable within their investment framework rather than systemic threats.
Opportunity Density
The manager states they 'enter 2024 with attractive opportunities across the sector landscape' and initiated multiple new positions during the quarter. They identify opportunities in energy transition, water technology, e-commerce, and biotechnology, suggesting a reasonably rich opportunity set despite acknowledging selectivity requirements.
Time Horizon
The investment approach emphasizes multi-year profit cycles and secular growth drivers that 'extend beyond short-term market cycles.' The manager discusses patience through volatility and long-term investment campaigns, with specific references to 'longer term investors' and multi-year recovery scenarios for companies like Equifax.
